Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Detaylı Bibliyografya
Asıl Yazarlar:	Chowdhury, O, O'Sullivan, J, Barkas, N, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A, Zhou, D, McMullin, M, Reiser, D, Zhong, J, Gale, R, Mead, A
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	American Society of Hematology 2018

Benzer Materyaller

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Yazar:: Chowdhury, O, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
Yazar:: Gowin KL, ve diğerleri
Baskı/Yayın Bilgisi: (2015-04-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Yazar:: Butt, N, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
Yazar:: Alessandra Carobbio, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
Yazar:: J.-J. Kiladjian, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Clonal evolution: a landmark of MPN evolution
Yazar:: Nabih Maslah, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
Yazar:: Claire Harrison, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
Yazar:: F. Stegelmann, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Primary myelofibrosis and its paraneoplastic stromal effects
Yazar:: Ayalew Tefferi
Baskı/Yayın Bilgisi: (2007-05-01)

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES
Yazar:: C. Harrison, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360–5 - Comment
Yazar:: Jürgen Thiele, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)

Patterns of conservation of spliceosomal intron structures and spliceosome divergence in representatives of the diplomonad and parabasalid lineages
Yazar:: Andrew J. Hudson, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
Yazar:: J. Mascarenhas, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN
Yazar:: Harrison, C, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
Yazar:: Robert Peter Gale, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Incidence of blast phase in myelofibrosis according to anemia severity
Yazar:: Barbara Mora, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
Yazar:: A. Kaifie, ve diğerleri
Baskı/Yayın Bilgisi: (2016-03-01)

Mpn-238 single-cell RNA profiling of myelofibrosis patients reveals pelabresib-induced decrease of megakaryocytic progenitors and normalization of CD4+ T cells in peripheral blood
Yazar:: Zavidij, O, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Pomalidomide-induced hypothyroidism
Yazar:: Sulaiman Haji Ali, ve diğerleri
Baskı/Yayın Bilgisi: (2017-12-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
Yazar:: Aaron T. Gerds, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Guideline for the diagnosis and management of myelofibrosis
Yazar:: Reilly, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Guideline for the diagnosis and management of myelofibrosis.
Yazar:: Reilly, J, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A
Yazar:: Brierley, CK, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
Yazar:: Tiziano Barbui, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Yazar:: Verstovsek, S, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

MPN Membangun Negara
Yazar:: Ishak, Mohamed Mustafa
Baskı/Yayın Bilgisi: (2010)

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
Yazar:: C. Cerchione, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
Yazar:: C. Harrison, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Low-dose thalidomide in myelofibrosis
Yazar:: Robert Weinkove, ve diğerleri
Baskı/Yayın Bilgisi: (2008-07-01)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Yazar:: Reilly, J, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis
Yazar:: Animesh Pardanani, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Yazar:: Reilly, J, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19
Yazar:: T. Barbui, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
Yazar:: V. Gupta, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
Yazar:: Claire N. Harrison, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Mutational spectrum defines primary and secondary myelofibrosis
Yazar:: Ken I. Mills, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Breakthrough infections in MPN-COVID vaccinated patients
Yazar:: Tiziano Barbui, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
Yazar:: Ruben Mesa, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Standard care and investigational drugs in the treatment of myelofibrosis
Yazar:: Daniela Barraco, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
Yazar:: Srdan Verstovsek, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)